Abstracts Archive - Page 1990 of 2425 - ACR Meeting Abstracts

Abstract Number: 935 • 2014 ACR/ARHP Annual Meeting
Targeting Glycolysis in Rheumatoid Arthritis
Monica Guma¹, Alessia Lodi², Ajit Divakaruni³, Anne Murphy³, Stefano Tiziani⁴ and Gary S. Firestein⁵, ¹Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ²nutritional Sciences, University of Texas at Austin, Austin, TX, ³Pharmacology, University of California, San Diego, La Jolla, CA, ⁴Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁵Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA
Background/Purpose: Many of the signaling pathways activated in inflammation have a profound effect on cell metabolism. However, little is known about metabolome in rheumatoid arthritis…
Abstract Number: 934 • 2014 ACR/ARHP Annual Meeting
Amelioration of Inflammatory Arthritis By Anti-TNF Therapy Is Associated with Restoration of Lymphatic Contraction
Echoe M. Bouta¹, Igor Kuzin², Karen de Mesy-Bentley¹, Ronald Wood³, Homaira Rahimi⁴, Rui-Cheng Ji⁵, Christopher T. Ritchlin⁶, Andrea Bottaro², Lianping Xing⁷ and Edward M. Schwarz⁸, ¹University of Rochester, Rochester, NY, ²Cooper Medical School, Camden, NJ, ³Department of Urology, University of Rochester Medical Center, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hospit, Rochester, NY, ⁵Department of Anatomy, Biology and Medicine, Oita University, Oita, Japan, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Pathology & Lab Medicine, University of Rochester, Rochester, NY, ⁸Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with episodic flares. In tumor necrosis factor transgenic (TNF-Tg) mice, a model of inflammatory-erosive arthritis,…
Abstract Number: 933 • 2014 ACR/ARHP Annual Meeting
A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
Hermine I. Brunner¹, Nicolino Ruperto², N Tzaribachev³, Gerd Horneff⁴, Carine Wouters⁵, Violeta Vladislava Panaviene⁶, Vyacheslav Chasnyk⁷, Carlos Abud-Mendoza⁸, Ruben Cuttica⁹, Andreas Reiff¹⁰, M Maldonado-Velázquez¹, Nadina Rubio-Pérez¹¹, Rik Joos¹², V Keltsev¹³, Evgeny Nasonov¹⁴, Daniel Kingsbury¹⁵, M Bandeira¹⁶, Earl Silverman¹⁷, F Weller-Heinemann¹¹, A van Royen-Kerkhof¹⁸, Alan M. Mendelsohn¹⁹, Lilianne Kim²⁰, Daniel Lovell²¹ and A Martini²², ¹PRCSG, Cincinnati, OH, ²Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ³PRINTO & PRCSG, Bramstedt, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵Pediatric Rheumatology, University Hosp Gasthuisberg, Leuven, Belgium, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Litovskaya Str., 2, Novartis Pharma, Saint-Peterburg, Russia, ⁸Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁹Tilcara 3023, Hospital de Ninos Pedro de Elizalde, Capital Federal, Argentina, ¹⁰Children’s Hospital of Los Angeles, Los Angeles, CA, ¹¹PRINTO, Genoa, Italy, ¹²UZ Gent, Gent, Belgium, ¹³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genoa, Italy, ¹⁴State Institute of Rheumatology of RAMS, Moscow, Russia, ¹⁵Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁶Pediatrics, Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, ¹⁷Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada, ¹⁸Department of Pediatric Immunology & Rheumatology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Immunology, Janssen Research & Development, LLC., Spring House, PA, ²⁰Janssen Research & Development, LLC., Spring House, PA, ²¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ²²Istituto Gaslini-PRINTO, Genova, Italy
Background/Purpose: To assess efficacy and safety of SC golimumab (GLM) in polyarticular pediatric juvenile idiopathic arthritis pts (aged 2 to
Abstract Number: 932 • 2014 ACR/ARHP Annual Meeting
MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Janneke Anink¹, Marieke H. Otten¹, Lisette W.A. van Suijlekom-Smit¹, Marion A.J. Van Rossum², Koert M. Dolman³, Esther P.A. Hoppenreijs⁴, Rebecca ten Cate⁵, Simona Ursu⁶, Lucy R Wedderburn⁷, Gerd Horneff⁸, Thomas Vogl^9,10, Dirk Föll^10,11, Johannes Roth^9,12 and Dirk Holzinger^10,13, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ³Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, ⁴Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁷Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁹Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁰Interdisciplinary Centre for Clinical Research IZKF, University Hospital Muenster, Muenster, Germany, ¹¹Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ¹²University Hospital Muenster, Muenster, Germany, ¹³Pediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany
Background/Purpose: Biological therapy has dramatically improved the treatment of patients with JIA. However, there is still a group of patients that shows a lack of…
Abstract Number: 931 • 2014 ACR/ARHP Annual Meeting
Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients
N.M. Wulffraat^1,2, N. Ruperto², H.I. Brunner³, S. Oliveira², Y. Uziel², K. Nistala², R. Cimaz², M. Ferrandiz², B. Flato², M.L. Gamir², I. Koné-Paut², C. Gaillez⁴, K. Lheritier⁴, K. Abrams⁵, A. Martini² and D.J. Lovell³, ¹Pediatric Rheumatology, UMC Utrecht, Utrecht, Netherlands, ²PRINTO-Istituto Gaslini, Genova, Italy, ³PRCSG, Cincinnati, OH, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Canakinumab, a selective, human, anti-interleukin (IL) -1β monoclonal antibody, is approved for the treatment of systemic juvenile idiopathic arthritis (SJIA) patients (≥ 2 years…
Abstract Number: 930 • 2014 ACR/ARHP Annual Meeting
An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Isabelle Koné-Paut², Bo Magnusson², Seza Ozen², Flavio Sztajnbok², Jordi Anton², Judith Barash², Reinhard Berner², Fabrizia Corona², Karine Lheritier³, Corine Gaillez³, Alberto Martini² and Daniel Lovell¹, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Novartis Pharma AG, Basel, Switzerland
Background/Purpose Systemic juvenile idiopathic arthritis (SJIA), an interleukin-1β (IL-1β)-mediated autoinflammatory disease, is characterized by recurrent flares of active disease. Canakinumab (CAN), a selective, human, anti-…
Abstract Number: 929 • 2014 ACR/ARHP Annual Meeting
Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study
Daniel B. Horton^1,2, Frank I. Scott IV^1,3, Kevin Haynes¹, Mary E. Putt¹, Carlos D. Rose², James D. Lewis^1,3 and Brian L. Strom^1,4, ¹Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Division of Rheumatology, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, ³Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: Dysregulation of the human microbiome has been implicated in the development of several autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease (IBD). Moreover,…
Abstract Number: 928 • 2014 ACR/ARHP Annual Meeting
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Alessandro Consolaro¹, Amita Aggarwal², Troels Herlin³, Olga Vougiouka⁴, Rubén Burgos-Vargas⁵, Ilonka Orban⁶, Nahid Shafaie⁷, Maria Trachana⁸, Lidia Rutkowska-Sak⁹, Ingrida Rumba-Rozenfelde¹⁰, Dimitrina Mihaylova¹¹, Alberto Martini^12,13 and Angelo Ravelli^1,14, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ⁵Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁷Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran, ⁸Aristotle University, Thessaloniki, Greece, ⁹Institute of Rheumatology, Warsaw, Poland, ¹⁰University of Latvia, Riga, Latvia, ¹¹University Children Hospital, Sofia, Bulgaria, ¹²Istituto Giannina Gaslini, Genova, Italy, ¹³University of Genova, Genova, Italy, ¹⁴Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose The epidemiology of juvenile idiopathic arthritis (JIA) is known to be variable worldwide and the therapeutic approach to JIA is not standardized. Moreover, the…
Abstract Number: 912 • 2014 ACR/ARHP Annual Meeting
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials
Rohit Aggarwal¹, Lisa G. Rider², Nicolino Ruperto³, Nastaran Bayat², Brian Erman⁴, Brian M. Feldman⁵, Adam M. Huber⁶, Chester V. Oddis⁷, Ingrid E. Lundberg⁸, Anthony A. Amato, MD^9,10, Robert G. Cooper, MD, FRCP¹¹, Hector Chinoy¹², Maryam Dastmalchi¹³, David Fiorentino¹⁴, David Isenberg¹⁵, James D. Katz¹⁶, Andrew L. Mammen¹⁷, Marianne de Visser¹⁸, Steven R. Ytterberg¹⁹, Katalin Danko²⁰, Luca Villa²¹, Mariangela Rinaldi²¹, Howard Rockette²², Peter A. Lachenbruch², Frederick W. Miller² and Jiri Vencovsky, MD, DSc²³, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁴Dermatology, Stanford University, Redwood City, CA, ¹⁵Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ¹⁸Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN, ²⁰Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²¹Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, ²²University of Pittsburgh, Pittsburgh, PA, ²³Institute of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: To develop consensus on definitions of improvement (DOIs) for minimal and moderate improvement (and draft preliminary criteria for major improvement) in adult dermatomyositis (DM)…
Abstract Number: 911 • 2014 ACR/ARHP Annual Meeting
Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-Kb-Mediated Inflammation
Nicholas A. Young¹, Lai-Chu Wu¹, Michael Bruss², Wael N. Jarjour³ and Dana P. Ascherman⁴, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Rheumatology, Miami VAMC, Miami, FL
Background/Purpose: The idiopathic inflammatory myopathies represent a group of autoimmune diseases that target muscle as well as extra-muscular organs, leading to significant morbidity and mortality. …
Abstract Number: 910 • 2014 ACR/ARHP Annual Meeting
The Selective Sphingosine-1- Phosphate Receptor 1/5 Modulator Siponimod (BAF312) Shows Beneficial Effects in Patients with Active, Treatment Refractory Polymyositis and Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind, Randomized Trial
Katalin Danko¹, Jiri Vencovsky², Ingrid E. Lundberg³, Anthony A Amato⁴, Chester V. Oddis⁵, Maria Molnar⁶, Antonette Mallari Moher⁷, Laurence Colin⁸, Florian Muellershausen⁹, David Lee¹⁰ and Peter Gergely⁹, ¹Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²Institute of Rheumatology, Charles University, Prague, Czech Republic, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary, ⁷Translational Medicine, Novartis Institutes for Biomedical Research (former emplyee), Basel, Switzerland, ⁸Novartis Pharma, Basel, Switzerland, ⁹Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, Basel, Switzerland
Background/Purpose Polymyositis and dermatomyositis (PM/DM) comprise a heterogeneous group of chronic inflammatory muscle diseases where infiltration of lymphocytes in the skeletal muscle plays a key…
Abstract Number: 909 • 2014 ACR/ARHP Annual Meeting
A Diagnostic Protocol for Giant Cell Arteritis (GCA) Using Ultrasound Assessment
Jennifer Piper¹, Ana Sofia Serafim¹, Cristina Ponte¹, Surjeet Singh², Bhaskar Dasgupta³, Wolfgang A. Schmidt⁴, Eugene McNally⁵, Andreas P. Diamantopoulos⁶, Andrew Hutchings⁷ and Raashid Luqmani⁸, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Sciences, Oxford, England, ³Department of Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁴Rheumatology, Immanuel Krankenhaus, Berlin, Germany, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, United Kingdom, ⁶Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁷Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁸Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom
Background/Purpose Ultrasound (US) has not yet superseded temporal artery biopsy as a diagnostic test. This may reflect poor consistency of the scanning technique, due to…
Abstract Number: 908 • 2014 ACR/ARHP Annual Meeting
Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission
Emanuela Bellis¹, Greta Carrara², Carlo Alberto Scirè², Alessandra Bortoluzzi³, Alberto Batticciotto⁴, Antonella Adinolfi⁵, Giovanni Cagnotto⁶, Marta Caprioli⁷, Marco Canzoni⁸, Francesco Cavatorta⁹, Fulvia Ceccarelli¹⁰, Orazio De Lucia¹¹, Valentina Di Sabatino¹², Antonella Draghessi¹³, Georgios Filippou¹², Ilaria Farina³, Maria Cristina Focherini¹⁴, Paola Frallonardo¹⁵, Alessandra Gabba¹⁶, Angelica Gattamelata¹⁰, Marwin Gutierrez¹³, Luca Idolazzi¹⁷, Filippo Luccioli¹⁸, Pierluigi Macchioni¹⁹, Marco Massarotti²⁰, Claudio Mastaglio²¹, Luana Menza²¹, Giulia Mirabelli¹⁸, Maurizio Muratore²², Simone Parisi²³, Valentina Picerno¹², Matteo Piga²⁴, Roberta Ramonda²⁵, Bernd Raffeiner²⁶, Daniela Rossi²⁷, Paola Rossini²⁸, Garifallia Sakellariou^29,30, Crescenzio Scioscia³¹, Carlo Venditti³², Annamaria Iagnocco¹⁰ and Marco Matucci-Cerinic³³, ¹Rheumatology, Ospedale Mauriziano, Turin, Italy, ²Italian Society for Rheumatology, Milan, Italy, ³A.O.U. S.Anna di Cona, Ferrara, Italy, ⁴L.Sacco University Hospital, Milan, Italy, ⁵Policlinico le Scotte, Siena, Italy, ⁶IRCCS Policlinico San Matteo, Pavia, Italy, ⁷Istituto di Cura Città di Pavia, Pavia, Italy, ⁸A.O. Sant'Andrea, Rome, Italy, ⁹A.O.U.P. Santa Chiara, Trento, Italy, ¹⁰Sapienza University of Rome, Rome, Italy, ¹¹Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ¹²University of Siena, Siena, Italy, ¹³Università Politecnica delle Marche, Jesi, Italy, ¹⁴Ospedale Infermi, Rimini, Italy, ¹⁵Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ¹⁶A.O.U. di Cagliari, Cagliari, Italy, ¹⁷Ospedale Civile Maggiore, Verona, Italy, ¹⁸University of Perugia, Perugia, Italy, ¹⁹Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ²⁰Istituto Clinico Humanitas, Rozzano, Italy, ²¹Moriggia-Pelascini, Gravedona, Italy, ²²Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy, ²³A.O. Città della Salute e della Scienza di Torino, Turin, Italy, ²⁴Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²⁵Rheumatology Unit, Department of Medicine, University of Padua, Padova, Italy, ²⁶Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ²⁷University of Turin, Turin, Italy, ²⁸P.O. “Destra Secchia”, Pieve di Coriano, Italy, ²⁹Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ³⁰Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ³¹University of Bari, Bari, Italy, ³²A.O. Rummo, Benevento, Italy, ³³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose Clinical remission is now an achievable goal in patients with rheumatoid arthritis (RA). Much has been done in order to better understand and define…
Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer¹ and Tore K. Kvien², ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…
Abstract Number: 906 • 2014 ACR/ARHP Annual Meeting
How Long Does Sonographic Joint Activity Continue in Clinically Remittive Joints of Patients with Rheumatoid Arthritis?
Miriam Gärtner¹, Farideh Alasthi², Gabriela Supp¹, Peter Mandl², Josef Smolen¹ and Daniel Aletaha¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III, Devision of Rheumatology, Medical University of Vienna, Vienna, Austria
How long does sonographic joint activity continue in clinically remittive joints of patients with rheumatoid arthritis? M. Gärtner, F. Alasthi, G. Supp, P. Mandl, JS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].